Genetic and Clinic of Mature Lymphoid Neoplasms has the following research output in the current window (1 September 2024 - 31 August 2025) of the Nature Index. Click on Count to view a list of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. The Food and Drug ...
The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...
News Medical on MSN
Disrupted genome architecture drives lymphoma development
Cancer isn't just about broken genes-it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services.
Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...
(RTTNews) - Incyte Corp. (INCY) said that the U.S. Food and Drug Administration has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor or FGFR inhibitor, for the treatment ...
Corvus Pharmaceuticals (CRVS) announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma ...
The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback